Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diarrhoea Predominant Irritable Bowel Syndrome Clear all
Completed Phase 4 Interventional

Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea

NCT03729271
View directory record Official record
Conditions
Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea
Interventions
Rifaximin, Glucose and lactulose hydrogen breath testing
Drug · Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 28, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Glutamine for the Treatment of Patients With Irritable Bowel Syndrome

NCT01414244
View directory record Official record
Conditions
Diarrhea-Predominant Irritable Bowel Syndrome
Interventions
Glutamine
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 72 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Sep 28, 2026, 5:44 PM EDT
Completed Not applicable Interventional

Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome

NCT01094041
View directory record Official record
Conditions
Diarrhea, Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Gluten free diet, Gluten rich diet
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 9, 2013 · Synced Sep 28, 2026, 5:44 PM EDT
Completed Phase 2 Interventional

A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT01844180
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
ONO-2952, ONO-2952 Matching Placebo
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
48
States / cities
Anniston, Alabama • Goodyear, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Sep 28, 2026, 5:44 PM EDT
Completed Phase 2 Interventional

A Study of BMS-562086 in Patients With Irritable Bowel Syndrome

NCT00399438
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Placebo, BMS-562086
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Sep 28, 2026, 5:44 PM EDT
Completed Phase 2 Interventional

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

NCT01494233
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
250 mg LX1033 tablets, Placebo tablet
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
81
States / cities
Huntsville, Alabama • Tempe, Arizona • Tucson, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Sep 28, 2026, 5:44 PM EDT
Terminated Phase 2 Interventional Results available

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

NCT04043455
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Olorinab, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
69
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 28, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

NCT01553591
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
257
States / cities
Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 214 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2018 · Synced Sep 28, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome

NCT02328547
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Fecal microbiota transplantation capsules, Placebo capsules
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
19 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Hamden, Connecticut • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 28, 2026, 5:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mediterranean Diet and the Gut Microbiome

NCT03269032
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
American Diet, Mediterranean-style Diet
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 28, 2026, 5:44 PM EDT
Completed Phase 3 Interventional

Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)

NCT01100684
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Asimadoline, Placebo
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
18 Years to 79 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
142
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 125 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 28, 2026, 5:44 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

NCT00394173
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea (IBS-D)
Interventions
DNK333, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
180 participants
Timeline
2006 – 2007
U.S. locations
37
States / cities
Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 28, 2026, 5:44 PM EDT
Completed Phase 3 Interventional

Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

NCT00067561
View directory record Official record
Conditions
Irritable Colon, Irritable Bowel Syndrome (IBS)
Interventions
Alosetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
177
States / cities
Birmingham, Alabama • Calera, Alabama • Tuscaloosa, Alabama + 149 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 28, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)

NCT01327300
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Mesalamine, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Sep 28, 2026, 5:44 PM EDT
Completed No phase listed Observational

Retrospective Study of IBS-D Patients Previously Receiving SBI

NCT02661425
View directory record Official record
Conditions
Diarrhoea Predominant Irritable Bowel Syndrome
Interventions
EnteraGam
Other
Lead sponsor
Entera Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Greenwich, Connecticut • Hamdon, Connecticut • Coral Springs, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2016 · Synced Sep 28, 2026, 5:44 PM EDT
Completed Phase 2 Interventional

A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome

NCT00101725
View directory record Official record
Conditions
Irritable Bowel Syndrome, Colonic Diseases, Diarrhea, Gastrointestinal Disease
Interventions
crofelemer
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
29
States / cities
Huntsville, Alabama • Chandler, Arizona • North Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 28, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea

NCT01130272
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
807 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
288
States / cities
Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 225 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Sep 28, 2026, 5:44 PM EDT
Completed Not applicable Interventional Results available

Gulf War Digestive Health Study

NCT00680836
View directory record Official record
Conditions
Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Interventions
Placebo, Rifaximin
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
35 Years to 72 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Sep 28, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

NCT01553747
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
232
States / cities
Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 189 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Sep 28, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

NCT03977155
View directory record Official record
Conditions
Diarrhea-predominant Irritable Bowel Syndrome
Interventions
BOS-589, Placebo
Drug
Lead sponsor
Boston Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
58
States / cities
Anniston, Alabama • Huntsville, Alabama • Chandler, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 28, 2026, 5:44 PM EDT
Terminated Phase 2 Interventional

Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

NCT06153420
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
CIN-103, Placebo
Drug
Lead sponsor
CinPhloro Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Dothan, Alabama • Huntsville, Alabama • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 28, 2026, 5:44 PM EDT
Completed Phase 2 Interventional

8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS

NCT00230581
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
DDP225
Drug
Lead sponsor
Dynogen Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Scottsdale, Arizona • St Louis, Missouri • Great Neck, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2007 · Synced Sep 28, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption

NCT03270085
View directory record Official record
Conditions
Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption
Interventions
Colesevelam, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Sep 28, 2026, 5:44 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia

NCT01268618
View directory record Official record
Conditions
IBS-D and Functional Dyspepsia
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
Sprim Advanced Life Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Duluth, Georgia • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Sep 28, 2026, 5:44 PM EDT